CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Prolonged-Release Melatonin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04067791
NCT04067791Phase 1Completed

A Randomized, Double-blind, Comparator-controlled, Cross-over Study to Investigate the Pharmacokinetics of Prolonged-release Melatonin Compared to Standard, Immediate-release Melatonin in Healthy Adults

Pharmavite LLC·interventional·Posted Aug 26, 2019·Updated Jun 9, 2020

In Brief

A Phase 1 clinical trial evaluating Prolonged-Release Melatonin and Immediate-Release Melatonin for Healthy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

A study comparing the pharmacokinetics of prolonged-release melatonin versus standard, immediate-release melatonin. Multiple blood draws over a 10-hour period will be analysed to determine the area under the curve, time to peak concentration, peak concentration, absorption rate constant, elimination rate constant, absorption half-life, and elimination half-life. Vital signs, hematology parameters, clinical chemistry parameters, and incidence of adverse events are also analysed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 26, 2019
Enrollment StartAug 1, 2019
Primary CompletionAug 27, 2019
TodayJul 1, 2026
Enrollment to primary: 26 daysPosted 6.8 years ago

Interventions

Prolonged-Release Melatonindietary

4.47 mg melatonin in a bi-layer prolonged-release capsule

Immediate-Release Melatonindietary

4.47 mg melatonin in a standard release bi-layer capsule